Proteomic analysis of HEK293 cells expressing non small cell lung carcinoma associated epidermal growth factor receptor variants reveals induction of heat shock response
© Kamath et al. 2015
Received: 29 May 2015
Accepted: 3 June 2015
Published: 12 June 2015
In view of the fact that certain non small cell lung carcinoma associated epidermal growth factor receptor mutations keep the receptor constitutively active, the downstream effectors of altered activity of mutant receptors are largely unknown. By 2D gel electrophoresis and MALDI-TOF/MS analysis, we showed that increased activity of EGFR mutants, L858R, L861Q and A871G induce heat shock proteins such as Hsp70, Hsp60, Hsp90B1, Hsp5a, Hsp71 and few transcriptional factors. Of which, Hsp70 was observed to be regulated more selectively to L861Q mutant. Our results suggest the possible role of heat shock proteins in lung tumor progression considering EGFR mutations.
To the editor
Large number of studies reported epidermal growth factor receptor mutations (EGFR) in non small cell lung carcinoma (NSCLC) patients worldwide, most commonly in Asian countries including India in the last decade [1, 2]. In vitro studies have demonstrated the contribution of EGFR mutations to uncontrolled tumor proliferation and evasion of programmed cell death in various cancers [3, 4] including lung tumorigenesis in transgenic mice models . It is known that a set of NSCLC associated EGFR mutations especially in tyrosine kinase (TK) domain have accounted for to have prognostic significance as they sensitize the receptor to TKI [6, 7]. Therefore, the question remains unanswered why NSCLC tumors with certain mutations respond to targeted drugs while others make the tumor resistant to the same drug . This implies the complexity of drug sensitivity in patients harboring EGFR mutations and the complexity may be due to altered activity of mutant receptors affecting various downstream molecules for tumor survival which are largely unknown. Till date, detection of EGFR mutations remains an important prognostic test, as FDA approved drugs including the drugs which are currently under development for NSCLC treatment target EGFR. Unfortunately, in spite of considering mutations for treatment prediction, prognosis of advanced stage tumors remains poor. At this juncture, identification of downstream effectors of altered mutant receptor activity with prognostic importance is essential. Uncovering of such molecules may also allow us to understand the lung tumor progression and complexity of drug sensitivity driven by receptor variants.
We initiated our study by screening FFPE lung tumor tissues derived from NSCLC patients from north Indian population for EGFR mutations by RT-PCR followed by sequencing after obtaining ethical approval and informed consent from patients. Detailed methodology was given in Additional file 1. Receptor activity and drug sensitivity was determined by measuring phosphorylation on tyr1068 residue of each mutant generated by site directed mutagenesis. Two amino acid substitutions, L861Q (10.5 %) and A871G (2.1 %) in exon21 and K879R (24.2 %) in exon22 of TK domain were detected (Additional file 2). Former two demonstrated increased receptor activity (Additional file 3), and sensitivity to TKI, Gefitinib more selectively (Additional files 4 and 5). While the latter one was found to be indistinguishable from wild type receptor with respect to its activity and drug sensitivity.
Differentially expressed proteins in cells expressing mutants vs. wild type EGFR identified by MALDI-TOF/MS analysis
L861Q vs. WT
A871G vs. WT
Heat shock cognate 71 kDa protein
Heat shock 70 kDa protein 1
Endoplasmin (GRP94) HSP90B1
60 kDa heat shock protein, mitochondrial
78 kDa GRP (HSP5A)
T-complex protein 1 subunit epsilon
Tubulin alpha-1B chain
Keratin, type I cytoskeletal 18, 19
Keratin, type II cytoskeletal 8
Actin, cytoplasmic 2
This study was funded by Indian Council of Medical Research (No. 5/13/94/2008- NCD III), New Delhi. India. We are grateful to Dr. Raju Rajala, OUHSC, USA for providing us with EGFR full length plasmid from which all receptor mutants were generated.
- Bell DW, Brannigan BW, Matsuo K, Finkelstein DM, Sordella R, Settleman J, et al. Increased prevalence of EGFR –mutant in lung cancer in women and in East Asian populations: analysis of estrogen related polymorphism. Clin Cancer Res. 2008;14(13):4079–84.PubMed CentralPubMedView ArticleGoogle Scholar
- Mehta J. Molecular epidemiology of epidermal growth factor receptor mutations in lung cancers in Indian population. Ind J Cancer. 2013;50(2):102–6.View ArticleGoogle Scholar
- Shin DY, Na II, Kim CH, Park S, Baek H, Yang SH. EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol. 2014;9(2):195–9.PubMedView ArticleGoogle Scholar
- Bos PD, Zhang XH, Nadal C, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459:1005–9.PubMed CentralPubMedView ArticleGoogle Scholar
- Pilot K, Zakowski MF, Fan PD, Sconfeld EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors founding human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 2006;20(11):1496–510.View ArticleGoogle Scholar
- Lynch TJ, Bell DW, Sordell R, Gurubhagavatulu S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to Gefitinib. New Eng J Med. 2004;350(21):2129–39.PubMedView ArticleGoogle Scholar
- Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response Gefitinib therapy. Science. 2004;304:1497–500.PubMedView ArticleGoogle Scholar
- Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New Engl J Med. 2005;352(8):786–92.PubMedView ArticleGoogle Scholar
- Bloomston M, Zhou JX, Rosemurgy AS, Frankel W, Muro-Cacho CA, Yeatman TJ. Fibrinogen gamma over expression in pancreatic cancer identified by large-scale proteomic analysis of serum samples. Cancer Res. 2006;66(5):2592–9.PubMedView ArticleGoogle Scholar
- Lai KC, Liu CJ, Chang KW, Lee TC. Depleting IFIT2 mediates atypical PKC signaling to enhance the migration and metastatic activity of oral squamous cell carcinoma cells. Oncogene. 2013;32(32):3686–97.PubMedView ArticleGoogle Scholar
- Wang HX, Liu YF, Yang SJ, Duan CG, Wang YX, Zhao J, et al. Expression of HSP70 Grp94 and IgG in human lung carcinoma. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2008;24(5):447–9.PubMedGoogle Scholar
- Małusecka E, Zborek A, Krzyzowska-Gruca S, Krawczyk Z. Expression of heat shock proteins HSP70 and HSP27 in primary non-small cell lung carcinomas.An immunohistochemical study. Anticancer Res. 2001;21(2A):1015–21.PubMedGoogle Scholar
- Zimmermann M, Nickl S, Lambers C, Hacker S, Mitterbauer A, Hoetzenecker K, et al. Discrimination of clinical stages in non-small cell lung cancer patients by serum HSP27 and HSP70: A multi-institutional case–control study. Clin Chim Acta. 2012;413:1115–20.PubMedView ArticleGoogle Scholar
- Li S, Wang R, Zhang M, Wang L, Cheng S. Proteomic analysis of non-small cell lung cancer tissue interstitial fluids. World J Surgical Oncol. 2013;11:173.View ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.